To understand prescription pattern of HAPIDÃ?Â®

A prospective, observational, real world surveillance to evaluate prescription pattern of HAPIDÃ?Â® (Un-denatured Type II Collagen and Aflapin) of Wockhardt Limited in the management of patients with Osteoarthritis

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/07/034607

Enrollment

3000

Registered

2021-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M199- Osteoarthritis, unspecified site

Interventions

Intervention1: HAPIDÃ?Â® Capsule containing Aflapin 100 mg and un-denatured type II collagen 40 mg: To be taken orally as per investigatorÃ¢â?¬â?¢s discretion. Control Intervention1: Not Applicable: N

Eligibility

Inclusion criteria

Inclusion criteria: Any adult patient of Osteoarthritis prescribed with HAPIDÃ?Â® (Un-denatured Type II Collagen and Aflapin) willing to provide written informed consent to share information

Exclusion criteria

Exclusion criteria: Not Applicable

Design outcomes

Primary

Measure	Time frame
1. Demographic characteristics Ã¢â?¬â?? Gender, Age, BMI 2. Clinical characteristics Ã¢â?¬â?? Clinical diagnosis, Kellgren and Lawrence system grade (0-4) 3. Treatment pattern of HAPIDÃ?Â® - Duration of HAPID, Type of therapy for Osteoarthritis, Type of Analgesic agents, Concomitant Illness (comorbidity)Timepoint: Day of Visit	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Khokan Debnath

Wockhardt Ltd.

KapilM@wockhardt.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026